[go: up one dir, main page]

EE04700B1 - Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid - Google Patents

Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid

Info

Publication number
EE04700B1
EE04700B1 EEP200100161A EEP200100161A EE04700B1 EE 04700 B1 EE04700 B1 EE 04700B1 EE P200100161 A EEP200100161 A EE P200100161A EE P200100161 A EEP200100161 A EE P200100161A EE 04700 B1 EE04700 B1 EE 04700B1
Authority
EE
Estonia
Prior art keywords
processes
slow
preparation
release
active compound
Prior art date
Application number
EEP200100161A
Other languages
English (en)
Estonian (et)
Inventor
Kanikanti Venkata-Rangarao
Rupp Roland
Brendel Erich
Weisemann Claus
Chantraine Ernst
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE200100161A publication Critical patent/EE200100161A/xx
Publication of EE04700B1 publication Critical patent/EE04700B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • General Preparation And Processing Of Foods (AREA)
EEP200100161A 1998-09-18 1999-09-17 Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid EE04700B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19842753A DE19842753A1 (de) 1998-09-18 1998-09-18 Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
PCT/EP1999/006882 WO2000016748A1 (de) 1998-09-18 1999-09-17 Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
EE200100161A EE200100161A (et) 2002-08-15
EE04700B1 true EE04700B1 (et) 2006-10-16

Family

ID=7881376

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100161A EE04700B1 (et) 1998-09-18 1999-09-17 Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid

Country Status (29)

Country Link
US (1) US6805881B1 (xx)
EP (1) EP1113787B1 (xx)
JP (1) JP2002526437A (xx)
KR (1) KR100660072B1 (xx)
CN (1) CN1178650C (xx)
AT (1) ATE260645T1 (xx)
AU (2) AU5861499A (xx)
BG (1) BG105325A (xx)
BR (1) BR9913839A (xx)
CA (1) CA2344372C (xx)
DE (2) DE19842753A1 (xx)
DK (1) DK1113787T3 (xx)
EE (1) EE04700B1 (xx)
ES (1) ES2215404T3 (xx)
HK (1) HK1040932B (xx)
HR (1) HRP20010198A2 (xx)
HU (1) HUP0103669A3 (xx)
ID (1) ID28735A (xx)
IL (2) IL141532A0 (xx)
NO (1) NO20011211L (xx)
NZ (1) NZ510563A (xx)
PL (1) PL195543B1 (xx)
PT (1) PT1113787E (xx)
RU (1) RU2235540C2 (xx)
SK (1) SK285099B6 (xx)
TR (1) TR200100756T2 (xx)
UA (1) UA73097C2 (xx)
WO (2) WO2000016747A1 (xx)
ZA (1) ZA200101485B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005012561B4 (de) 2005-03-18 2008-06-19 Christian Beer Verfahren zum Betrieb eines Werkstück-Transfersystems
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
CN100448432C (zh) * 2006-10-26 2009-01-07 徐竹青 高溶出度尼莫地平分散片的制备方法
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7952167B2 (en) * 2007-04-27 2011-05-31 Taiwan Semiconductor Manufacturing Company, Ltd. Scribe line layout design
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
TWI468191B (zh) * 2009-01-28 2015-01-11 Novartis Ag 有機化合物之調配物
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
EP4247354A4 (en) * 2020-11-18 2025-02-19 Fb-Hrs, Llc COMPOSITIONS CONTAINING DOFETILIDE AND MEXILETINE AND THEIR USES
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5482525A (en) 1977-12-13 1979-06-30 Aisan Ind Co Ltd Exhaust gas recirculation system
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
JPS63222121A (ja) * 1987-03-10 1988-09-16 Nippon Soda Co Ltd 徐放性ゲル製剤
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
JPH02167229A (ja) * 1988-09-01 1990-06-27 Kureha Chem Ind Co Ltd かわらたけ由来の蛋白多糖体の粒状製剤
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH03101615A (ja) * 1989-09-14 1991-04-26 Sumitomo Pharmaceut Co Ltd 胃内滞留型持続性製剤
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
JP3059004B2 (ja) * 1992-09-18 2000-07-04 ダイセル化学工業株式会社 アルカリ水溶液に対する溶解性の高い低置換度ヒドロキシプロピルセルロース及びその製造法
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2725624B1 (fr) 1994-10-14 1997-01-17 Jouveinal Inst Rech Procede de preparation de formes pharmaceutiques a liberation controlee
DE19504831A1 (de) 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose

Also Published As

Publication number Publication date
HUP0103669A3 (en) 2006-07-28
JP2002526437A (ja) 2002-08-20
BG105325A (bg) 2001-11-30
IL141532A (en) 2007-03-08
ATE260645T1 (de) 2004-03-15
US6805881B1 (en) 2004-10-19
CA2344372C (en) 2009-12-22
ZA200101485B (en) 2002-02-22
WO2000016748A1 (de) 2000-03-30
HRP20010198A2 (en) 2002-04-30
EP1113787A1 (de) 2001-07-11
SK285099B6 (sk) 2006-06-01
DE19842753A1 (de) 2000-03-23
UA73097C2 (en) 2005-06-15
HK1040932A1 (en) 2002-06-28
NO20011211D0 (no) 2001-03-09
DK1113787T3 (da) 2004-05-17
PL346535A1 (en) 2002-02-11
CN1317959A (zh) 2001-10-17
CA2344372A1 (en) 2000-03-30
NO20011211L (no) 2001-03-09
KR20010073172A (ko) 2001-07-31
HUP0103669A2 (hu) 2002-01-28
RU2235540C2 (ru) 2004-09-10
WO2000016747A1 (de) 2000-03-30
SK3722001A3 (en) 2001-10-08
IL141532A0 (en) 2002-03-10
HK1040932B (zh) 2005-08-05
TR200100756T2 (tr) 2001-07-23
BR9913839A (pt) 2001-06-12
DE59908764D1 (de) 2004-04-08
PL195543B1 (pl) 2007-09-28
EE200100161A (et) 2002-08-15
AU5861499A (en) 2000-04-10
ES2215404T3 (es) 2004-10-01
AU6191899A (en) 2000-04-10
CN1178650C (zh) 2004-12-08
AU750617B2 (en) 2002-07-25
KR100660072B1 (ko) 2006-12-22
NZ510563A (en) 2002-10-25
PT1113787E (pt) 2004-07-30
EP1113787B1 (de) 2004-03-03
ID28735A (id) 2001-06-28

Similar Documents

Publication Publication Date Title
EE200100161A (et) Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid
IL135130A0 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
NO995006D0 (no) Nye forbindelser
CA2427815A1 (en) Controlled release hydrocodone formulations
YU35893A (sh) Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba
ES2172239T3 (es) Sistema osmotico de liberacion de farmacos.
BG104727A (en) Pharmaceutical composition of topiramate
BR9405843A (pt) Processo para reduzir perda óssea e uso de um composto
HUP0002296A2 (hu) Sertralinsók és a sertralin elnyújtott felszabadulását biztosító dózisformák
BR9612291A (pt) Forma de dosagem sólida bioadesiva
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ZA200205512B (en) Novel substituted benzimidazole dosage forms and methods of using same.
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
AU3533395A (en) Oral sustained-release preparation
IS3789A7 (is) Aðferð við framleiðslu lyfjaskammta í föstu formimeð tempraðri losun virks þáttar
PT1121109E (pt) Formulacao bifasica contendo tramadol
IL110025A0 (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
HU0100122D0 (en) Use of tiludronic acid and derivatives thereof in poultry for preparation of a medicinal product for preventing and treating osteoporosis

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20070917